US judge dismisses Seroquel suit alleging fraudulent marketing
This article was originally published in Scrip
Executive Summary
A US federal judge in Florida has tossed (dismissed?) a putative class action brought by several union health and welfare benefit funds that claimed they were duped into paying hundreds of millions of dollars for AstraZeneca's antipsychotic Seroquel (quetiapine fumarate) as a result of an alleged fraudulent off-label campaign which violated "the Racketeer Influenced and Corrupt Organizations (RICO) statute and state consumer protection laws as well as common law claims for fraud, misrepresentation, civil conspiracy and unjust enrichment".